Using the transcriptional data obtained from cancer patients treated with PD-1 therapy and a newly established murine preclinical anti-PD-1 therapy-refractory model, NANOG was identified as a factor that enhanced patients’ resistance to immune-checkpoint inhibitors. The gene discussed is PDCD1; the disease is cancer.